Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

PHASTAR Names Chris Schoonmaker as Chief Operations Officer

   77
PHASTAR Names Chris Schoonmaker as Chief Operations Officer

PHASTAR Names Chris Schoonmaker as Chief Operations Officer

London, UK and Durham, NC - June 29, 2022 – PHASTAR, a global specialist biometrics contract research organization (CRO) offering industry leading data management, data science, statistical consulting, and clinical trial reporting services, today announces that Chris Schoonmaker has joined the company as Chief Operations Officer. Chris will direct PHASTAR’s operational strategy with a key focus on ensuring quality deliverables and providing a positive customer experience. 

uMotif – the patient-first data capture and decentralized clinical trials platform – announces $25.5m of new investment from a fund managed by Athyrium Capital Management

   249
uMotif – the patient-first data capture and decentralized clinical trials platform – announces $25.5m of new investment from a fund managed by Athyrium Capital Management

uMotif – the patient-first data capture and decentralized clinical trials platform – announces $25.5m of new investment from a fund managed by Athyrium Capital Management

LONDON and NEW YORK, May 25, 2022-- uMotif today announced a new investment of $25.5m from a fund managed by Athyrium Capital Management, LP, the New York-based investment firm.  The new funding will support continued scale up of uMotif's unique patient-first software platform for clinical research.